If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

Sanofi (SNY) and Regeneron’s (REGN) Dupixent has gained EU approval as the first targeted therapy in more than ten years for chronic spontaneous urticaria, offering a new option for patients who do ...

Please provide your email address to receive an email when new articles are posted on . Urticaria patients taking Dupixent experienced an 8.64-point reduction in itch and 15.86-point reduction in ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Safety results in all LIBERTY-CUPID Phase 3 trials were generally consistent with ...

Hives (urticaria) are raised, itchy bumps on your skin. If you get itchy hives that come and go mostly every day for over six weeks, you might have a skin condition known as chronic spontaneous ...

Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and Regeneron have presented data from a phase 3 trial that could help push ...

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...